Structure based drug design and molecular docking studies of anti-cancer molecules paclitaxel, etoposide and topotecan using Novel ligands.
Tubulin is the biochemical target for several clinically used anticancer drugs as it helps in the formation of mitotic spindle formation during mitosis stage of cell division. Many of the anti-cancerdrugs are known to interact with tubulin and microtubules including some plant alkaloids such as paclitaxel, etoposide and topotecan. insilico drug design of these molecules were performed prior to testing these drugs invitro. In silico drug design of these anti-cancer drugs becomes a challenge due to the complex structure of target protein. This challenge was overcome by generating the structure of target protein (tubulin) by homology modeling. In this study,computer aided drug designing approach was applied to predict the suitable docking site in target protein and the interaction of tubulin protein with paclitaxel, etoposide and topotecan was explored by molecular docking using Schrödinger software. Docking score and glide energy were determined with ligands to validate their anticancer properties in order to reduce experimental efforts of studying animal model. The results indicate that etoposide is the best drug for tubulin with a docking score of -4.916 and glide energy of -46.470cal/mol.